Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IP6K1 | Q92551 | 6/20 | 0.41 |
| ▸ | BRD4 | O60885 | 2/20 | 0.38 |
| ▸ | AVPR1B | P47901 | 1/20 | 0.37 |
| ▸ | NR3C2 | P08235 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.35 |
| ▸ | AR | P10275 | 1/20 | 0.35 |
| ▸ | HCRTR1 | O43613 | 2/20 | 0.35 |
| ▸ | HCRTR2 | O43614 | 2/20 | 0.35 |
| ▸ | IDH1 | O75874 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | SLC13A5 | Q86YT5 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8049691 | 0.91 | IP6K1 (0.40) | IP6K1BRD4AVPR1BNR3C2PGR | |
| SCHEMBL1590667 | 0.85 | IDO1 (0.44) | IP6K1BRD4PGRL3MBTL1 | |
| SCHEMBL16837199 | 0.85 | IP6K1 (0.41) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL1479873 | 0.83 | AVPR1B (0.42) | IP6K1BRD4AVPR1BNR3C2PGR | |
| SCHEMBL1480622 | 0.82 | IP6K1 (0.39) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL1480632 | 0.81 | IP6K1 (0.39) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL1480365 | 0.81 | IP6K1 (0.38) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL1788080 | 0.81 | PGR (0.40) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL16837188 | 0.81 | PGR (0.40) | IP6K1AVPR1BNR3C2PGRNR3C1 | |
| SCHEMBL1479564 | 0.81 | AVPR1B (0.39) | IP6K1AVPR1BNR3C2PGRNR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9403796-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2016-08-02 | — | — | US | disclosed |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-09-18 | — | — | US | disclosed |
| US-8703775-B2 | Amidomethyl-substituted oxindole derivatives and the use thereof for the treatment of vasopressin-dependent illnesses | AbbVie Deutschland GmbH & Co. KG (DE) | 2014-04-22 | — | — | US | disclosed |
| EP-2231643-B1 | Amidomethyl-substituted oxindole derivatives and their use in the manufacture of a medicament for the treatment of vasopressin-dependent diseases | ABBOTT GMBH & CO KG (DE) | 2012-10-31 | — | — | EP | disclosed |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2011-03-31 | — | — | US | disclosed |
| EP-2231643-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | Abbott GmbH & Co. KG (DE) | 2010-09-29 | — | — | EP | disclosed |
| WO-2009071687-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
| WO-2009071687-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | ABBOTT GMBH & CO. KG (DE) | 2009-06-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110077253-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | IP6K1 2918/4885BRD4 960/4885AVPR1B 2/4885 |
| US-20140275110-A1 | AMIDOMETHYL-SUBSTITUTED OXINDOLE DERIVATIVES AND THE USE THEREOF FOR THE TREATMENT OF VASOPRESSIN-DEPENDENT ILLNESSES | AVPR2, AVPR1B, AVPR1A | IP6K1 2918/4885BRD4 960/4885AVPR1B 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.